Cover:
-Boeing's trajectory shifted dramatically from a success story to turmoil, particularly following the crashes of two 737 MAX jets in 2018 and 2019, resulting in significant operational and reputational setbacks. By the end of 2024, Boeing had delivered only 265 737-model jets, substantially below its targets and markedly fewer than the 396 delivered in 2023. The stock price had fallen to 55% below its peak in March 2019. However, the appointment of Kelly Ortberg as CEO in July 2024 marked a turning point. Ortberg, an experienced aerospace engineer, has revitalized Boeing by enhancing supplier relationships, restructuring management, reallocating development resources, and prioritizing proximity to production sites. His leadership has spurred a 7% increase in stock value since his appointment, indicating a potential recovery for the company as investors regain confidence in its future prospects.
Interview:
-Rithm's CEO, Michael Nierenberg, highlights that commercial real estate prices in these cities remain approximately 40% lower than pre-COVID levels, making it an appealing investment. He expects the demand for office space to grow as employees return to work, supported by a favorable economic environment characterized by reduced interest rates and strong leasing quarters. Big banks and tech companies are encouraging employees to return to the office, with some advocating for a full five-day work week. In line with this trend, Rithm Capital, a real estate investment company offering a dividend yield above 9%, plans to acquire Paramount Group, a real estate investment trust, for $1.6B. This acquisition is based on the optimism that white collar workers will commute more, especially in New York and San Francisco.
Tech Trader:
-Shares of Meta Platforms fell 11% following their earnings report, despite a 26% increase in sales for the third quarter. This decline was attributed to rising expenses from significant investments in artificial intelligence (AI). CEO Mark Zuckerberg noted that capital expenditures forecast for 2025 had been revised higher for the third time this year, with expectations for continued spending into the next year. He expressed confidence in the core business's returns, emphasizing the importance of not underinvesting. However, investors showed increasing concern as total costs rose 32%, outpacing revenue growth, leading to a decrease in the operating margin by 2.7 percentage points. Analysts anticipate a rise in depreciation expenses—expected to increase by 48% next year—transforming Meta into a more asset-heavy company that will impact its financial structure for years. The expense growth stems from a hiring surge of AI researchers at high salary levels, as reflected in the 35% increase in research and development costs and an 18% rise in share-based compensation within three months.
The Trader:
-Vertex Pharmaceuticals has faced significant challenges following the failure of its next-generation painkiller, VX-993, in a Phase 2 drug trial, leading to an 11% drop in stock prices since early August. However, there is optimism surrounding its non-opioid painkiller, Journavax, and the robust performance of its cystic fibrosis business. Upcoming third-quarter earnings reports are anticipated to reverse the negative trend, with analysts projecting sales growth exceeding 10%, reaching approximately $3.06 billion, primarily driven by the cystic fibrosis segment, while Journavax is estimated to contribute about $23 million. Vertex has a consistent track record of exceeding earnings forecasts, having surpassed sales expectations in 16 of the last 20 quarters. Analysts expect this trend to continue, with cystic fibrosis products particularly highlighted as strong performers.
-Defensive stocks, typically expected to perform well during economic uncertainty, have underperformed significantly in 2023 despite slowing job growth and concerns around the economy. The Consumer Staples Select Sector SPDR ETF has returned only 1.7%, while the S&P 500 has gained 18%. The low performance of defensive stocks is peculiar given the current sluggish manufacturing sector. However, market analysts suggest this trend may reverse soon, as the price ratios of defensive stocks compared to economically sensitive ones are at historic lows, potentially signaling a forthcoming catch-up for defensive sectors.
Features:
-Investors looking for non-AI related stocks should consider Boston Scientific. The growth in AI stocks raises concerns over potential market corrections, thus prompting a shift to medical-device companies that continuously innovate for patient care. Companies like Intuitive Surgical and Abbott Laboratories have experienced significant stock increases due to their advancements. In particular, Boston Scientific is positioned to benefit from the expected growth in cardiac procedures, projected to reach about $92B by 2030. With forecasted sales of $20B by 2025—$13B of which will come from its cardiovascular segment—Boston Scientific's stock, currently trading at $100, might have room for growth as analysts expect a 13% rise in cardiovascular product sales next year. The company has a history of exceeding earnings estimates, further strengthening investor confidence.
-President Trump and Chinese leader Xi Jinping are set to meet to devise a strategy for mending US-China relations, potentially involving reduced tariffs on fentanyl-related products from China. This meeting concludes a week of negotiations aimed at finalizing trade agreements. Key topics include U.S. tariffs on fentanyl, China's resumption of U.S. agricultural purchases, mutual shipping fees, and export controls. Additionally, the meeting may address Beijing's approval of TikTok's divestiture and U.S. language surrounding Taiwan. Despite hopes for a significant agreement, experts suggest a modest deal may emerge, focusing on maintaining rare earth shipments and avoiding further tariff increases.
Europe:
-Novo Nordisk is aggressively pursuing a $6B cash acquisition of the anti-obesity biotech Metsera, surpassing Pfizer’s $4.9B offer, which has escalated their bidding war. Pfizer characterized Novo's bid as an attempt to suppress competition and circumvent antitrust laws, highlighting Novo's dominant position in the market. Novo's shares have plummeted over 60% since mid-2024, raising questions about its stability. The bid indicates a bold, possibly desperate move by Novo’s new leadership amidst ongoing challenges, including a hostile regulatory environment, as the Trump administration looks to lower drug prices. The situation intensifies as Novo engages with Pfizer, a rival noted for strong ties to the current administration.
Emerging Markets:
-Argentina's recent parliamentary elections saw right-wing leader Javier Milei of La Libertad Avanza party emerge victorious, a development viewed positively by U.S. Treasury Secretary Scott Bessent, as it ensures repayment of a $20B loan. This election outcome may signal the decline of the Peronist party, which has historically driven Argentina into economic turmoil and frustration among citizens. Despite Argentina’s recurring patterns of economic collapse since its independence in 1816, the nation has occasionally pursued reform, such as in the 1930s and the 1990s under President Carlos Menem. However, these reforms were often followed by a return to unsustainable political choices that led to further crises, including a significant default in 2020. In contrast, Milei’s campaign promises included a stark message against financial irresponsibility and a radical proposal to cut government spending to combat hyperinflation, which approached 200%. The electorate's support for Milei, characterized by his unconventional appearance and promise of immediate pain for future gain, marks a shift in voter priorities.
Commodities:
-Rare earth materials have become a focal point of concern for investors due to their volatility and implications for American manufacturing amid ongoing trade tensions. As of Tuesday trading, shares of leading US rare earth miners, such as MP Materials, USA Rare Earth, and Ramaco Resources, have seen a significant average increase of over 210% this year, despite a nearly 30% drop in the past week. The stocks were anticipated to retreat further ahead of potential US-China negotiations regarding rare earth export controls, following Chinese threats to limit exports, highlighting China's dominance in the sector with around 85% of global processing capacity.
While the global utilization of rare earth elements is currently modest, around 390,000 metric tons of rare earth oxides were mined in 2024, demand has surged by 350% over the last decade, driven by their essential role in various applications from electronics to defense. Recognizing the need for a stable supply, the US Defense Department secured a comprehensive deal with MP Materials in July, which involves an equity stake and a price floor for rare earth products, aimed at diminishing reliance on Chinese sources. In addition, Ramaco Resources leverages its metallurgical coal operations to contribute towards achieving rare earth independence.
Streetwise:
-Tesla, although primarily recognized as a car manufacturer, also identifies itself as a "physical AI" company engaged in two emerging AI ventures: operating robotic taxis and deploying humanoid assistants in homes and businesses. These initiatives currently contribute minimally to Tesla's income and stock market valuation. Recently, the company's visibility has diminished, particularly as CEO Elon Musk stepped back from the public eye after a controversial stint leading the Department of Government Efficiency—an experience that drew mixed evaluations regarding its taxpayer savings impact. Investors expressed concerns over Musk's political engagements and their potential repercussions on Tesla's brand. According to Wedbush Securities analyst Dan Ives, this situation has led to significant stock declines, with estimates of 15%-20% permanent demand loss attributed to perceived brand damage. Tesla's market value has plummeted to approximately $777B, resulting in its ranking dropping to 10th among major tech companies, significantly overshadowed by competitors and even trailing behind firms involved in unrelated industries.